Targeted Routine Antenatal Anti-D Prophylaxis in the Prevention of RhD Immunisation - Outcome of a New Antenatal Screening and Prevention Program

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Tiblad, Eleonor ^a   Taune Wikman, Agneta ^a   Ajne, Gunilla ^b   Blanck, Agneta ^b   Jansson, Yvonne ^b   Karlsson, Anita ^c   Nordlander, Elisabeth ^b   Holländer, Bibi Shassti ^b   Westgren, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c University Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RHESUS D ANTIBODY;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; GENOTYPE; GESTATION PERIOD; HEALTH PROGRAM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NON INVASIVE MEASUREMENT; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRENATAL CARE; PRENATAL PERIOD; PRENATAL SCREENING; PROPHYLAXIS; PROSPECTIVE STUDY; RHESUS IMMUNIZATION; RHESUS INCOMPATIBILITY; RISK ASSESSMENT; RISK REDUCTION; SWEDEN; TREATMENT OUTCOME;

COHORT STUDIES; DIAGNOSTIC TESTS, ROUTINE; FEMALE; GENOTYPING TECHNIQUES; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRENATAL DIAGNOSIS; RH ISOIMMUNIZATION; RH-HR BLOOD-GROUP SYSTEM; RHO(D) IMMUNE GLOBULIN; SWEDEN;

EID: 84881170637     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070984     Document Type: Article

References (28)

1. Gottvall T, Filbey D, (2008) Alloimmunization in pregnancy during the years 1992-2005 in the central west region of Sweden. Acta Obstet Gynecol Scand 87: 843-848.
2. Howard H, Martlew V, McFadyen I, Clarke C, Duguid J, et al. (1998) Consequences for fetus and neonate of maternal red cell allo-immunisation. Arch Dis Child Fetal Neonatal Ed 78: F62-66.
3. Tiblad E, Kublickas M, Ajne G, Bui TH, Ek S, et al. (2011) Procedure-related complications and perinatal outcome after intrauterine transfusions in red cell alloimmunization in Stockholm. Fetal Diagn Ther 30: 266-273.
4. Van Kamp IL, Klumper FJ, Oepkes D, Meerman RH, Scherjon SA, et al. (2005) Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization. Am J Obstet Gynecol 192: 171-177.
5. Crowther C, Middleton P (2000) Anti-D administration after childbirth for preventing Rhesus alloimmunisation. Cochrane Database Syst Rev: CD000021.
6. Bowman J, (2006) Rh-immunoglobulin: Rh prophylaxis. Best Pract Res Clin Haematol 19: 27-34.
7. Bowman JM, Pollock JM, Penston LE, (1986) Fetomaternal transplacental hemorrhage during pregnancy and after delivery. Vox Sang 51: 117-121.
8. Pilgrim H, Lloyd-Jones M, Rees A (2009) Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation. Health Technol Assess 13: iii, ix-xi, 1-103.
9. Turner RM, Lloyd-Jones M, Anumba DO, Smith GC, Spiegelhalter DJ, et al. (2012) Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality. PLoS One 7: e30711.
10. Koelewijn JM, de Haas M, Vrijkotte TG, Bonsel GJ, van der Schoot CE, (2008) One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 48: 1721-1729.
11. Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, et al. (2003) A review of the clinical effectiveness and cost-effectiveness of routine anti-D prophylaxis for pregnant women who are rhesus-negative. Health Technol Assess 7: iii-62.
12. Faas BH, Beuling EA, Christiaens GC, von dem Borne AE, van der Schoot CE, (1998) Detection of fetal RHD-specific sequences in maternal plasma. Lancet 352: 1196.
13. Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, et al. (1997) Presence of fetal DNA in maternal plasma and serum. Lancet 350: 485-487.
14. Lo YM, Hjelm NM, Fidler C, Sargent IL, Murphy MF, et al. (1998) Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma. N Engl J Med 339: 1734-1738.
15. Muller SP, Bartels I, Stein W, Emons G, Gutensohn K, et al. (2008) The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 48: 2292-2301.
16. Finning K, Martin P, Summers J, Massey E, Poole G, et al. (2008) Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 336: 816-818.
17. Geifman-Holtzman O, Grotegut CA, Gaughan JP, (2006) Diagnostic accuracy of noninvasive fetal Rh genotyping from maternal blood-a meta-analysis. Am J Obstet Gynecol 195: 1163-1173.
18. Legler TJ, Muller SP, Haverkamp A, Grill S, Hahn S, (2009) Prenatal RhD Testing: A Review of Studies Published from 2006 to 2008. Transfus Med Hemother 36: 189-198.
19. Van der Schoot CE, Soussan AA, Koelewijn J, Bonsel G, Paget-Christiaens LG, et al. (2006) Non-invasive antenatal RHD typing. Transfus Clin Biol 13: 53-57.
20. Clausen FB, Christiansen M, Steffensen R, Jorgensen S, Nielsen C, et al. (2012) Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 52: 752-758.
21. Wikman AT, Tiblad E, Karlsson A, Olsson ML, Westgren M, et al. (2012) Noninvasive Single-Exon Fetal RHD Determination in a Routine Screening Program in Early Pregnancy. Obstet Gynecol.
22. Lee BK, Ploner A, Zhang Z, Gryfelt G, Wikman A, et al. (2011) Constructing a population-based research database from routine maternal screening records: a resource for studying alloimmunization in pregnant women. PLoS One 6: e27619.
23. Crowther CA, Keirse MJ (2000) Anti-D administration in pregnancy for preventing rhesus alloimmunisation. Cochrane Database Syst Rev: CD000020.
24. Koelewijn JM, de Haas M, Vrijkotte TG, van der Schoot CE, Bonsel GJ, (2009) Risk factors for RhD immunisation despite antenatal and postnatal anti-D prophylaxis. BJOG 116: 1307-1314.
25. Bowman JM, Pollock JM, (1987) Failures of intravenous Rh immune globulin prophylaxis: an analysis of the reasons for such failures. Transfus Med Rev 1: 101-112.
26. Tiblad E, Wikman A, Rane A, Jansson Y, Westgren M, (2012) Pharmacokinetics of 250 mug anti-D IgG in the third trimester of pregnancy: An observational study. Acta Obstet Gynecol Scand 91: 587-592.
27. Jones ML, Wray J, Wight J, Chilcott J, Forman K, et al. (2004) A review of the clinical effectiveness of routine antenatal anti-D prophylaxis for rhesus-negative women who are pregnant. BJOG 111: 892-902.
28. NICE (2008) Routine antenatal anti-D prophylaxis for women who are rhesus D negative. London: National Institute for Health and Clinical Excellence.